- Home
- ICLR vs FMS Comparison
ICLR vs FMS Comparison
Compare ICLR & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- FMS
- Stock Information
- Founded
- ICLR 1990
- FMS 1996
- Country
- ICLR Ireland
- FMS Germany
- Employees
- ICLR N/A
- FMS N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- FMS Misc Health and Biotechnology Services
- Sector
- ICLR Health Care
- FMS Health Care
- Exchange
- ICLR Nasdaq
- FMS Nasdaq
- Market Cap
- ICLR 14.5B
- FMS 14.6B
- IPO Year
- ICLR 1998
- FMS 1996
- Fundamental
- Price
- ICLR $175.83
- FMS $25.61
- Analyst Decision
- ICLR Buy
- FMS Hold
- Analyst Count
- ICLR 13
- FMS 1
- Target Price
- ICLR $210.67
- FMS $30.00
- AVG Volume (30 Days)
- ICLR 1.2M
- FMS 328.6K
- Earning Date
- ICLR 10-22-2025
- FMS 08-05-2025
- Dividend Yield
- ICLR N/A
- FMS 2.23%
- EPS Growth
- ICLR 13.11
- FMS 23.39
- EPS
- ICLR 9.73
- FMS 2.62
- Revenue
- ICLR $8,089,820,000.00
- FMS $22,922,038,756.00
- Revenue This Year
- ICLR N/A
- FMS $2.38
- Revenue Next Year
- ICLR $1.73
- FMS $3.41
- P/E Ratio
- ICLR $18.06
- FMS $19.40
- Revenue Growth
- ICLR N/A
- FMS 0.53
- 52 Week Low
- ICLR $125.10
- FMS $18.93
- 52 Week High
- ICLR $328.35
- FMS $30.46
- Technical
- Relative Strength Index (RSI)
- ICLR 57.64
- FMS 52.22
- Support Level
- ICLR $174.48
- FMS $24.80
- Resistance Level
- ICLR $181.51
- FMS $25.12
- Average True Range (ATR)
- ICLR 5.15
- FMS 0.30
- MACD
- ICLR 0.16
- FMS 0.21
- Stochastic Oscillator
- ICLR 78.82
- FMS 97.07
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.